PIPELINE
The technology platform is under development in two different areas. (1) Photochemical lysis (PCL), inducing selective light-triggered cell lysis, which may enhance yield and purity in viral vector manufacturing. (2) Photochemical internalisation (PCI), inducing light-triggered endosomal release, which may unlock the potential of a wide array of modalities.
See more details regarding development status under the pipeline section.
Status: Enhancing viral vector manufacturing using PCL
The PCL technology has been demonstrated with adherent and suspension producer cells, and is now being scaled to benchtop bioreactor.
Status: Modifying intracellular trafficking for intratumoural immunotherapy
Exploration of intratumoural immunotherapy by an industry PhD candidate grant (2023-2025) supported by the Research Council of Norway, aiming at identifying novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with such treatments.
Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through a Phase I study in healthy subjects. Link to publication Frontiers in Immunology
Status: Site-directed intracellular nucleic acid delivery for use in dermatology
Preclinical experiments have shown that PCI can substantially improve the effect of important classes of nucleic acids like mRNA, siRNA and DNA.
An ex vivo wound model study demonstrated significant PCI-mediated delivery of mRNA in a simplified model employing primary human cells ex vivo. Extensive in vivo animal data indicate that PCI strongly enhances nucleic acid delivery in the skin.